ALMS · Alumis Inc. · Stock research

Current Thesis

Alumis is a clinical-stage immunology company whose entire equity value runs through one molecule: envudeucitinib (ESK-001), a next-generation, highly selective oral TYK2 inhibitor for psoriasis and lupus. The narrative detonated on 2026-01-06 when Phase 3 psoriasis topline moved the stock +95.31% in a single session, and it has since ground from a sub-$10 pre-catalyst base to ~$28 (up ~625% over twelve months into July 24, 2026). The psoriasis leg is now largely de-risked — full ONWARD1/ONWARD2 data on 2026-03-28 showed PASI 90 of 68.0%/62.1% and PASI 100 of 41.0%/39.5% at Week 24 across 1,700+ patients, cross-trial the leading skin clearance among next-generation oral therapies. What an investor is buying at this price is the next binary: the LUMUS Phase 2b topline in systemic lupus (SLE), anticipated Q3 2026 with enrollment complete. The calendar has now rolled inside that window, so the readout is undated and imminent. A clean hit re-rates the platform beyond dermatology into a multi-billion indication; a primary-endpoint miss caps the name as one more oral psoriasis pill in a crowded field. This is an event, not a trend to chase.

Bullish and bearish views on Alumis Inc.

The model's bull view on Alumis Inc. (ALMS), in brief: Best-in-class Phase 3 efficacy (full data 2026-03-28): PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across ONWARD1/ONWARD2; management frames this as leading skin clearance versus next-gen oral peers including the entrenched incumbent Sotyktu. The bear view: Crowded oral autoimmune field: Sotyktu (BMS deucravacitinib) is the established oral TYK2, and Takeda's zasocitinib is advancing a competing next-gen molecule — a cross-trial efficacy edge does not guarantee formulary share or pricing power. Both cases follow in full.

Bull Case

• Best-in-class Phase 3 efficacy (full data 2026-03-28): PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across ONWARD1/ONWARD2; management frames this as leading skin clearance versus next-gen oral peers including the entrenched incumbent Sotyktu.
• Proven narrative velocity: the 2026-01-06 topline (PASI 75 74%, sPGA 0/1 59% at Week 16) produced a +95.31% single-day move — the market has demonstrated it pays up for this readout profile.
• Asymmetric lupus optionality: the LUMUS Phase 2b SLE topline is anticipated Q3 2026 with enrollment complete. TYK2 sits on the type-I interferon axis central to lupus biology; a positive read opens a large indication no oral TYK2 has yet cracked.
• Funded through both catalysts: $569.5M cash and marketable securities at 2026-03-31, runway stated through Q4 2027 — covers the psoriasis NDA and the lupus readout with no forced raise.
• NDA on the calendar: envudeucitinib plaque-psoriasis NDA targeted for H2/Q4 2026, reaffirmed on the 2026-05-14 Q1 call — a step from clinical asset toward commercial.
• Sell-side still lifting: consensus Strong Buy, average price target ~$40 (up from ~$38.50 in early July); HC Wainwright raised its target to $40 from $20 with a Buy — targets rising is the signature of a narrative the Street hasn't fully priced.

Bear Case

• Crowded oral autoimmune field: Sotyktu (BMS deucravacitinib) is the established oral TYK2, and Takeda's zasocitinib is advancing a competing next-gen molecule — a cross-trial efficacy edge does not guarantee formulary share or pricing power.
• Pure cash burn: Q1 2026 (reported 2026-05-14) showed a net loss of $93.1M with revenue collapsing to $1.7M from $17.4M a year prior; no meaningful product revenue before 2027 at the earliest.
• Priced near the range top: ~$28 against a 52-week range of $3.25–$31.35, roughly 10% under the high after a ~625% twelve-month run — a great deal of good news is embedded ahead of the lupus print.
• LUMUS is Phase 2b in the hardest indication: SLE is the immunology graveyard, and a primary-endpoint miss could round-trip a large slice of the post-January re-rate in a single gap.
• Serial issuance into strength: a $17.00 offering (20.3M shares) closed 2026-01-09 and roughly $345.1M gross was raised around the March results — the market gets tapped when the tape is strong.
• Reverse-merger overhang: the ACELYRIN combination (closed 2025-05-21, $238.1M, 48.65M shares issued) inflated the share count into the current move.

Setup & Price Structure

• Last at $28.00 (July 24, 2026 close, -1.06% on the day, intraday range $26.94–$28.51); market cap ~$3.57B on ~127.5M shares.
• 52-week range $3.25–$31.35: the stock sits at the top of a multi-month base, ~10% below the $31.35 high, which now functions as overhead supply and the breakout trigger.
• The April–June advance built a rising base from ~$20 to ~$28; a weekly close below $22 breaks that structure.
• Structurally clean but event-loaded: buying near 52-week highs ahead of an undated, now-live binary is a coin-flip on the readout. The disciplined stance is a small probe or standing aside until the name either bases lower or the topline clears — an accelerating tape does not mitigate a Phase 2b gap.

Catalyst Calendar (next 30 days)

• LUMUS Phase 2b SLE topline — anticipated Q3 2026 (undated; ~2026-09-15 mid-quarter placeholder): enrollment complete; the window is now live, so any session from late July onward carries binary headline risk. This is the dominant catalyst.
• Q2 2026 earnings — est. ~2026-08-13 (not confirmed): a hard-dated checkpoint where management typically reaffirms the LUMUS and NDA timelines; not thesis-driving on its own for a pre-revenue name.
• Competitor read-across: any BMS Sotyktu or Takeda zasocitinib data landing in the window can reprice ALMS independent of its own pipeline.

Elapsed catalysts

• Envudeucitinib psoriasis NDA submission — targeted H2/Q4 2026 (reaffirmed 2026-05-14): timing updates likely at the next print. (passed 87d ago)

What Would Change Our Mind

• Bull confirmation: LUMUS hits the SLE primary endpoint — the platform re-rates beyond dermatology and a multi-billion TAM opens; a clean beat that also carries price through $31.35 on volume converts the setup from event-bet to trend-follow.
• Thesis break: a weekly close below $22 loses the April–June rising base; a LUMUS primary-endpoint miss caps the name as a psoriasis-only pill and would round-trip a large slice of the post-January gains. A theme flip toward SATURATED — if Takeda or BMS data undercuts the differentiation — would compound either.
• Because the readout is undated and imminent, invalidation here is event-driven first and level-driven second: a fresh position near highs is exposed to a binary gap in both directions before any moving average is tested.

Correlation Notes

• Single-molecule idiosyncratic risk: the whole equity story is envudeucitinib, so fundamental correlation to the broad index is low. The reported beta of -0.71 is an artifact of the isolated January spike, not a genuine macro hedge — do not treat it as defensive.
• Peer read-across dominates the tape between prints: BMS (Sotyktu) and Takeda (zasocitinib) TYK2 data can move ALMS independent of its own pipeline.
• Biotech beta: the name trades with XBI/IBB on risk-on/risk-off and the rate regime for long-duration clinical assets, but through Q3 the LUMUS readout will swamp every other input.